Import from '@/components/mdx'

Low-Dose Naltrexone While Breastfeeding: What You Need to Know

What Is Low-Dose Naltrexone and Why Do Postpartum Women Use It?

Low-dose naltrexone is naltrexone, an FDA-approved opioid antagonist, taken at doses far below those used in addiction treatment. Standard naltrexone is approved at 50 mg/day for opioid and alcohol use disorder. LDN repurposes the same molecule at roughly 1.5 to 4.5 mg/night, a dose range that is entirely off-label and requires compounding from a specialty pharmacy.

The proposed mechanism at low doses is transient opioid receptor blockade, which is thought to trigger a rebound increase in endogenous opioid production and to modulate microglial activity and inflammatory cytokines. The evidence base for this mechanism comes largely from small trials and animal studies rather than large randomized controlled trials in humans.

Postpartum and breastfeeding women ask about LDN for several reasons:

• Autoimmune flares that accelerate after delivery (Hashimoto thyroiditis, multiple sclerosis, Crohn disease, lupus, rheumatoid arthritis)
• Fibromyalgia, which disproportionately affects women and may worsen postpartum
• Postpartum thyroiditis, a condition affecting up to 5% of women in the first year after delivery and sometimes complicated by inflammatory thyroid pain
• Chronic fatigue or central sensitization syndromes

These are real conditions causing real suffering. The question of whether LDN is safe during breastfeeding deserves a direct, evidence-grounded answer rather than vague reassurance.

How Naltrexone Gets Into Breast Milk

Pharmacokinetics That Matter for Nursing Mothers

Naltrexone is a small molecule with high oral bioavailability (roughly 5 to 40%, highly variable) and a volume of distribution of approximately 19 L/kg, meaning it distributes extensively into tissues, including likely into mammary gland tissue. Its molecular weight is 341 Daltons, below the 500-Dalton threshold typically associated with significant milk transfer.

The drug is metabolized rapidly to 6-beta-naltrexol, an active metabolite that retains opioid-blocking activity and has a longer half-life of approximately 13 hours compared to naltrexone's 4-hour half-life. Both compounds would be expected to appear in breast milk based on these physicochemical properties.

What the Human Data Actually Shows

This is where the evidence becomes sparse. LactMed, the National Institutes of Health database on drugs and lactation, states that no published data exist on the use of naltrexone during breastfeeding at any dose. The database notes that because of limited oral bioavailability in the infant and the small amounts expected in milk, low-level naltrexone exposure might not cause recognizable harm in most nursing infants, but this conclusion is theoretical, not empirically derived.

In animal models, naltrexone administered to lactating rats does transfer to pups through milk. A 1988 study by Zagon and McLaughlin showed that neonatal rat pups exposed to naltrexone through maternal milk had altered neurological development, with changes in body weight gain and opioid receptor density in the brain. These are animal findings, not human findings, and extrapolation must be done carefully. Rat neonates are not human newborns. Still, the findings raise a biologically plausible concern about endogenous opioid signaling disruption during a sensitive developmental period.

No human pharmacokinetic milk study has quantified naltrexone or 6-beta-naltrexol concentrations in milk at any dose, standard or low. This gap is a direct consequence of the historical exclusion of lactating women from clinical pharmacology research.

Pregnancy Safety: What the Data Shows Before You Even Reach Breastfeeding

FDA Labeling and Animal Reproductive Toxicity

The FDA label for naltrexone 50 mg tablets classifies the drug under the older Pregnancy Category C, meaning animal studies have shown adverse fetal effects and no adequate, well-controlled human studies exist. The prescribing information notes that in rats and rabbits, naltrexone was not teratogenic at doses up to 30 mg/kg/day, but higher doses produced embryotoxicity. At very high doses in rats (200 mg/kg/day), increased fetal loss was observed.

The human pregnancy database for standard-dose naltrexone is small and largely from women treated for opioid use disorder. There is no published human safety database for compounded LDN in pregnancy.

LDN During Pregnancy: A Specific Gap

Because LDN is compounded and off-label, it has not been studied in pregnant women in any structured way. Case reports and patient forums contain anecdotal accounts of women continuing LDN into pregnancy, but no prospective registry or cohort study has followed these pregnancies systematically. ACOG has not issued a specific statement on LDN in pregnancy or lactation, which itself reflects how limited the formal evidence base is.

If you are pregnant or planning pregnancy while taking LDN, discontinue the drug and discuss alternatives with your prescriber before conception or as soon as pregnancy is confirmed. This is not a drug for which the evidence supports a "continue and monitor" approach during pregnancy or lactation at this time.

Pregnancy and Lactation Safety: The Full Picture

Below is a structured framework for thinking about LDN across the perinatal period, because the risk profile shifts at each stage.

Trying to Conceive

LDN is increasingly prescribed off-label for immune modulation in women with recurrent implantation failure or suspected autoimmune subfertility. Some reproductive endocrinologists use it in this context. The evidence is preliminary: a small 2022 pilot study in women with recurrent pregnancy loss found no safety signals at doses of 1.5 to 4.5 mg, but the numbers were far too small for conclusions. ASRM does not include LDN in its guidelines on recurrent pregnancy loss.

If you are trying to conceive while on LDN, you and your prescriber need an explicit plan for when to stop. Stopping before a confirmed positive pregnancy test is the most conservative and defensible approach.

During Pregnancy

Stop LDN. There is no adequate human safety data for use during pregnancy at any dose. The FDA label's Pregnancy Category C designation means theoretical harm cannot be excluded. Given that endogenous opioid signaling plays documented roles in fetal brain development, placental function, and uterine contractility, blocking opioid receptors even transiently during organogenesis or later fetal development carries theoretical risk with no quantified human benefit.

Standard naltrexone at 50 mg is sometimes continued in pregnancy to prevent opioid relapse, a situation where the benefit of preventing maternal overdose and neonatal abstinence syndrome from illicit opioids clearly outweighs theoretical risk. That benefit-risk calculation does not apply to LDN prescribed for inflammation or fibromyalgia.

Breastfeeding and Postpartum

LactMed explicitly states there are no published data on naltrexone use during breastfeeding, making a recommendation to continue LDN while nursing not supportable by current evidence. The theoretical concern specific to breastfeeding is that naltrexone and 6-beta-naltrexol in breast milk could occupy opioid receptors in the nursing infant. Endogenous opioids (beta-endorphin, enkephalins) are present in breast milk itself and are thought to contribute to infant gut maturation, pain modulation, and possibly mother-infant bonding behaviors. Blocking these receptors, even at low drug concentrations, during the first months of life is a plausible concern that cannot be dismissed without human data.

Contraception Requirement

LDN is not classified as a teratogen requiring formal contraceptive counseling in the way that, for example, isotretinoin is. There is no mandatory REMS program for LDN. However, because the drug is not proven safe in pregnancy and has no studied human pregnancy outcomes at LDN doses, reliable contraception is advisable for any woman of reproductive age taking LDN who does not intend pregnancy, and a clear plan for stopping should be in place before conception is attempted.

The Evidence Gap: What Has Not Been Studied in Women

Women have been systematically excluded from pharmacokinetic research during pregnancy and lactation for decades. The absence of LDN milk-transfer data is not unique to this drug. It reflects a broader pattern that the NIH has acknowledged and is actively working to address through initiatives like the Task Force on Research Specific to Pregnant Women and Lactating Women.

What this means practically: when LactMed says "no data," it does not mean the drug is safe or unsafe. It means no one has looked. The precautionary stance the medical community takes is to treat unknown as potentially harmful when the drug is not necessary for maternal survival and safer alternatives exist.

For the specific conditions LDN is used to treat postpartum, here is what has been studied in breastfeeding women:

• Fibromyalgia: Low-impact aerobic exercise, cognitive behavioral therapy, and low-dose tricyclic antidepressants (amitriptyline, which has more lactation data) are first-line options that do not require stopping breastfeeding.
• Autoimmune thyroiditis / Hashimoto disease: Levothyroxine replacement, which is safe in breastfeeding, addresses the hypothyroid component. LDN's role here is unproven even outside of pregnancy.
• Rheumatoid arthritis / lupus postpartum flare: Hydroxychloroquine and low-dose prednisone both have substantial lactation safety data and are generally considered compatible with breastfeeding.
• Multiple sclerosis: Specific disease-modifying therapies have varied lactation profiles; a neurologist familiar with postpartum MS management should be involved.

Who Should Not Take LDN While Breastfeeding (and Who Might Have the Most to Gain When Data Arrive)

Breastfeeding is not the only consideration in this decision. The right approach depends on how severe your underlying condition is, whether effective alternatives exist, and how long you plan to nurse.

Avoid LDN while breastfeeding if:

• Your infant is premature or has neurological vulnerabilities, since even speculative opioid receptor disruption carries more weight in a fragile nervous system
• Your condition has FDA-approved or well-studied alternatives compatible with lactation
• You are in the first six weeks postpartum, when infant liver metabolism is least mature and drug clearance is slowest
• You have any history of neonatal opioid withdrawal from a previous pregnancy, suggesting your infant may be more sensitive to opioid receptor modulation

The situation where the calculus becomes harder:

A woman with a severe autoimmune disease, for whom LDN has been the only well-tolerated option after failing multiple other drugs, faces a genuinely difficult choice between her own health and the precautionary stance on breastfeeding. In this situation, the conversation should include a maternal-fetal medicine specialist or a lactation pharmacologist, not just a primary prescriber. Shared decision-making with full disclosure of the evidence gaps is appropriate. The decision to stop breastfeeding to continue a medication that meaningfully improves maternal quality of life is also a valid choice that deserves respect, not judgment.

Practical Steps If You Are Currently Taking LDN and Breastfeeding

If you started or continued LDN postpartum without specific guidance on breastfeeding safety, you are not alone, and the following steps are reasonable:

1. Contact your prescribing clinician today to discuss a plan. Do not stop abruptly without a conversation, because your underlying condition may need an immediate bridge therapy.
2. Ask your clinician to consult LactMed directly or to contact the InfantRisk Center (infantrisk.com), which provides evidence-based drug-in-lactation consultations.
3. If you choose to continue LDN temporarily while you arrange an alternative, timing doses at the end of your longest sleep stretch and feeding before the next dose (when drug levels are at their lowest) is sometimes discussed as harm reduction. This approach is based on pharmacokinetic logic, not studied efficacy, and should not substitute for stopping the drug.
4. If you decide to stop breastfeeding to maintain LDN therapy for a serious condition, work with a lactation consultant on safe weaning, and ensure your infant's pediatrician is aware.

Compounded LDN: An Additional Layer of Uncertainty

Standard 50 mg naltrexone tablets are FDA-approved and manufactured under GMP standards. Compounded LDN at 1.5 to 4.5 mg is mixed by a compounding pharmacy using the active pharmaceutical ingredient. FDA compounding regulations apply, but the final product has not undergone the same bioavailability testing or quality control as an approved drug.

This matters for breastfeeding in a specific way: dose accuracy in compounded products can vary. A 2016 analysis published in JAMA Internal Medicine found that compounded drugs frequently deviate from labeled potency. If a compounded LDN capsule delivers 6 mg instead of 3 mg, the effective milk-level exposure to the infant would double. Parents and clinicians cannot verify this without independent assay.

This compounding variability is not a reason to dismiss LDN as a concept, but it is one more reason why continuing it during breastfeeding without human safety data is a decision that carries more unknowns than the simple pharmacokinetic story about a small-molecule drug might suggest.

What We Need: A Call for Research

The postpartum period is one of the most immunologically active phases of a woman's life. Conditions like Hashimoto thyroiditis, rheumatoid arthritis, multiple sclerosis, and lupus can flare dramatically in the months after delivery. Women in this situation deserve options backed by real data.

The single most useful thing that could happen in this space is a pharmacokinetic milk-transfer study measuring naltrexone and 6-beta-naltrexol in breast milk from lactating women at LDN doses, paired with infant serum sampling. This study design is standard, feasible, and ethically conducted all the time for other drugs. The fact that it has not been done for LDN by 2025 is a reflection of the historical neglect of postpartum women in drug research, not of any particular danger that makes the study impossible.

Until that study exists, the recommendation stands: the evidence does not support LDN use during breastfeeding, and clinicians should not reassure patients otherwise.

The Bottom Line for Your Next Appointment

If you are breastfeeding and considering LDN, or already taking it, bring these specific questions to your clinician:

• "What is the LactMed recommendation for naltrexone and is my compounded LDN formulation covered by that assessment?"
• "Is there a lactation-compatible alternative for my specific condition?"
• "If I stop LDN, what is the plan to manage my [autoimmune condition / fibromyalgia / thyroiditis] during the postpartum period?"
• "If I need to continue LDN, how do we document this as a shared decision with full acknowledgment of the evidence gap?"

Your clinician's ability to answer these questions specifically, with reference to the actual evidence rather than general reassurance, is a signal of whether you have the right support for this decision.